Microbiome–Gut–Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders
- 11 May 2023
- journal article
- editorial
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (6) , 692-695
Abstract
The gut–brain axis (GBA) refers to the sophisticated bidirectional communication system connecting the digestive system with the central nervous system. This interaction is enabled by a series of intricate signaling processes, encompassing various neuro-immune and hormonal pathways. The association between the gut microbiome and mental health has garnered immense scientific and public interest, driven by an enhanced understanding of the microbiome’s role in facilitating communication between the gut and the brain. This Patent Highlight discloses methods for promoting the colonization of spore-forming bacteria in the gastrointestinal track. These methods include administering a serotonin receptor agonist, such as psilocybin, psilocin, N,N-dimethyltryptamine, bufotenine, 5-methoxy-N,N-dimethyltryptamine, lysergic acid diethylamide, ergine, mescaline, 3,4-methylenedioxyamphetamine, 2,5-dimethoxy-4-methylamphetamine, and others.Keywords
This publication has 6 references indexed in Scilit:
- Short-Chain Fatty Acids in the Microbiota–Gut–Brain Axis: Role in Neurodegenerative Disorders and Viral InfectionsACS Chemical Neuroscience, 2023
- Major depressive disorder and the gut microbiome: what is the link?General Psychiatry, 2023
- Acute sleep deprivation exacerbates systemic inflammation and psychiatry disorders through gut microbiota dysbiosis and disruption of circadian rhythmsMicrobiological Research, 2022
- The microbiome-gut-brain axis in nutritional neuroscienceNutritional Neuroscience, 2022
- Psychedelics therapeutics: What we know, what we think, and what we need to researchNeuropharmacology, 2022
- Differential co-expression networks of the gut microbiota are associated with depression and anxiety treatment resistance among psychiatric inpatientsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2022